EcoDrugPlus

Phosphodiesterase 9a

Ensembl ID : ENSPPRG00000008728
Gene Symbol: PDE9A
3 Cross references
280 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSPPRG00000023766
Gene Symbol: PIK3R1
4 Cross references
203 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSPPRG00000006838
Gene Symbol: PIK3R2
4 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSPPRG00000008668
Gene Symbol: PIK3R3
4 Cross references
274 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSPPRG00000007100
Gene Symbol: PIK3R5
4 Cross references
254 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSPPRG00000018256
Gene Symbol: PLA2G5
4 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSPPRG00000007477
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSPPRG00000013281
Gene Symbol: PLA2G10
3 Cross references
249 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSPPRG00000021685
Gene Symbol: GART
4 Cross references
215 Possible Orthologues:

Plasminogen

Ensembl ID : ENSPPRG00000007637
Gene Symbol: PLG
3 Cross references
240 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSPPRG00000023677
Gene Symbol: PLAT
4 Cross references
204 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSPPRG00000022317
Gene Symbol: PTAFR
4 Cross references
224 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).